Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children
- 13 December 2023
- journal article
- letter
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (3) , 788-790
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical TrialAmerican Journal of Respiratory and Critical Care Medicine, 2023
- Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del AlleleAmerican Journal of Respiratory and Critical Care Medicine, 2023
- Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GIJournal of Cystic Fibrosis, 2022
- Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and IvacaftorJournal of Cystic Fibrosis, 2021
- Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftorPediatric Pulmonology, 2020
- Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm studyThe Lancet Respiratory Medicine, 2016